Last 28 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.85 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.63 | 3.48 | 2.30 | 1.50 | 0.78 | 0.90 | 0.81 | 1.21 | 1.56 | 1.46 | 1.72 | 0.96 | 0.82 | 0.86 | 0.86 | 0.90 | 1.00 | 0.98 | 1.11 | 1.58 | 2.20 |
| — | +285.4% | +184.3% | +24.0% | -50.2% | -38.3% | -53.1% | +25.8% | +88.5% | +70.0% | +100.9% | +6.5% | -17.3% | -12.5% | -22.7% | -43.0% | -54.7% | -59.6% | -70.2% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.25 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -44.0% | -15.6% | -12.8% | -11.8% | -10.7% | -13.4% | -8.5% | -7.8% | -6.3% | -7.8% | -8.4% | -5.2% | -8.1% | -6.5% | -11.4% | -4.8% | -4.2% | 34.2% | -2.9% | -7.5% | -3.8% |
| — | -16.3% | -50.9% | -50.7% | -69.8% | -72.7% | -0.5% | -51.6% | +21.9% | -18.8% | +25.6% | -8.0% | -94.2% | -119.1% | -296.6% | +36.0% | -8.5% | +1113.9% | -13603.3% | +45.4% | +39.0% | |
| ROA | -41.1% | -14.0% | -11.7% | -10.9% | -10.1% | -12.7% | -8.1% | -7.5% | -6.1% | -7.4% | -8.0% | -4.9% | -7.7% | -6.2% | -10.8% | -4.5% | -3.9% | 31.7% | -2.8% | -7.3% | -3.8% |
| — | -10.0% | -44.5% | -45.5% | -65.8% | -71.3% | -1.5% | -53.7% | +21.1% | -19.7% | +26.1% | -7.0% | -99.6% | -119.6% | -289.4% | +37.7% | -2.1% | +1055.9% | -13595.0% | +43.8% | +37.3% | |
| ROIC | -43.5% | -15.9% | -13.1% | -12.3% | -10.8% | -12.7% | -8.4% | -8.0% | -6.8% | -8.4% | -9.0% | -8.9% | -8.8% | -7.7% | -12.5% | -6.7% | -7.4% | 60.2% | -6.9% | -7.1% | -4.0% |
| — | -25.9% | -56.2% | -54.9% | -58.4% | -51.6% | +7.5% | +10.3% | +22.1% | -8.7% | +27.6% | -32.8% | -17.9% | -112.8% | -81.2% | +6.3% | -86.8% | +1334.4% | -797.3% | +86.9% | +77.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | — | — |
| — | +108.6% | +95.2% | +80.1% | -32.4% | -25.9% | -55.2% | -53.9% | -69.1% | -66.8% | -45.0% | -18.5% | +57.8% | +572.4% | +175.7% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.00 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.25 | 8.42 | 10.28 | 10.25 | 10.45 | 9.83 | 11.62 | 13.53 | 24.46 | 28.87 | 20.33 | 17.07 | 20.33 | 25.32 | 15.25 | 21.09 | 21.47 | 10.04 | 18.68 | 25.25 | 41.82 |
| — | -14.4% | -11.5% | -24.3% | -57.3% | -65.9% | -42.8% | -20.7% | +20.3% | +14.0% | +33.3% | -19.1% | -5.3% | +152.2% | -18.4% | -16.5% | -48.7% | -83.3% | -58.7% | +70.3% | +45.8% | |
| Quick Ratio | 10.25 | 8.42 | 10.28 | 10.25 | 10.45 | 9.83 | 11.62 | 13.53 | 24.46 | 28.87 | 20.33 | 17.07 | 20.33 | 25.32 | 15.25 | 21.09 | 21.47 | 10.04 | 18.68 | 25.25 | 41.82 |
| — | -14.4% | -11.5% | -24.3% | -57.3% | -65.9% | -42.8% | -20.7% | +20.3% | +14.0% | +33.3% | -19.1% | -5.3% | +152.2% | -18.4% | -16.5% | -48.7% | -83.3% | -58.7% | +70.3% | +45.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CGEM stock.
Cullinan Therapeutics, Inc.'s current P/E is -3.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cullinan Therapeutics, Inc.'s business trajectory between earnings reports.